Tevogen Bio Holdings Inc.
TVGNHealthcare|Biotechnology|US
$5.59
+0.03 (+0.54%)
Cash / Share
$0.28
About
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Stock Price
-76.2%(1Y)
1M
-20.8%
3M
-13.6%
6M
-25.3%
YTD
-66.2%
1Y
-76.7%
3Y
-99.0%
5Y
-98.9%
Pipeline Summary
1 total trials1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Completed: 1
Key Facts
Market Cap$23.3M
Employees18 (+0% YoY)
CEORyan H. Saadi
IPO DateJan 5, 2022
Beta0.20
52-Week Range$3.636 – $25.12
Avg Volume10,117
ExchangeNASDAQ
Websitetevogen.com
Ownership
Float25.5%
Shares Outstanding4.2M
Recent Insider Trades
Saadi Ryan H.AWARD
Nov 2, 202650,000,000 shares
Saadi Ryan H.AWARD
Sep 14, 20268,000,000 shares
Desai KirtiAWARD
Sep 14, 2026750,000 shares
Goh Keow LinAWARD
Sep 11, 202675,000 shares
PODLOGAR SUSAN MAWARD
Sep 11, 202675,000 shares
Peers
Recent News
Tevogen Bio (NASDAQ:TVGN) Stock Falls 1.6% – Time to Sell?
Oct 15, 2026 · defenseworld.net
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Oct 8, 2026 · globenewswire.com
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Oct 8, 2026 · globenewswire.com
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Sep 30, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:38 AM